依瑞奈尤单抗在偏头痛患者中的中枢效应:事件相关功能成像研究
该研究对27例偏头痛患者在三叉神经伤害性刺激范式下进行fMRI扫描,比较依瑞奈尤单抗70 mg给药前与给药后2周的变化。结果显示,依瑞奈尤单抗可降低右侧丘脑、右侧颞中回、右侧舌回、左侧岛盖及双侧小脑多个簇的激活;在应答者中,给药后下丘脑激活显著降低(t=4.78;对比估计值29.79 [90%CI 19.53-40.05]),提示依瑞奈尤单抗可能不仅具有外周作用,还具有中枢效应。
要点
- 依瑞奈尤单抗可降低偏头痛患者三叉神经伤害性刺激下的多个脑区激活。
- 应答者给药后下丘脑激活显著降低,非应答者未见此变化。
- 依瑞奈尤单抗可能并非纯外周性偏头痛治疗,还具中枢效应。
核心结论
- 依瑞奈尤单抗可能不仅作用于外周,还具有中枢效应,表现为多个脑区激活降低及应答者下丘脑激活显著减少。
研究设计与样本
- 对27例偏头痛患者在依瑞奈尤单抗70 mg给药前和给药后2周进行fMRI扫描,采用已建立的三叉神经伤害性刺激范式。
主要发现
- 在全部27例患者中,依瑞奈尤单抗导致右侧丘脑(对侧于刺激侧)、右侧颞中回、右侧舌回、左侧岛盖及双侧小脑多个簇激活降低。
- 在相同头痛状态的应答者(n=9)与非应答者(n=8)比较中,仅应答者给药后下丘脑激活显著降低(t=4.78;对比估计值29.79 [90%CI 19.53-40.05])。
- 以绝对头痛天数作为回归变量时,下丘脑激活降低的发现得到确认。
临床怎么用
- 依瑞奈尤单抗的临床获益可能部分通过中枢机制介导,支持其不仅限于外周CGRP受体阻断。
- 下丘脑激活降低或可作为预测或评估依瑞奈尤单抗应答的潜在影像学标志物,但需进一步验证。
局限性
- 样本量较小(总27例,应答者9例、非应答者8例),结果需更大样本验证。
- 研究未明确区分中枢效应是外周感觉输入调节后的继发改变还是直接中枢作用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To determine whether erenumab, a new monoclonal antibody to the calcitonin gene-related peptide (CGRP) receptor, exerts functional central effects in migraineurs by performing functional imaging scans on patients treated with erenumab. METHODS: We conducted an fMRI study on 27 patients with migraine using a well-established trigeminal nociceptive paradigm, examining patients before and 2 weeks after administration of the CGRP receptor antibody erenumab 70 mg. RESULTS: Comparing both visit days in all patients (n = 27) revealed that erenumab leads to a decrease in activation in the right thalamus (i.e., contralateral to the stimulated side), right middle temporal gyrus, right lingual gyrus, left operculum, and several clusters on both sides of the cerebellum. Furthermore, when responders (n = 9) and nonresponders (n = 8) of the respective same headache state were compared, we found a significant reduction of hypothalamic activation after the administration of erenumab in responders only (t = 4.78; contrast estimate 29.79 [90% confidence interval 19.53-40.05]). This finding of reduced hypothalamic activation was confirmed when absolute headache days was used as a regressor. INTERPRETATION: These findings suggest that erenumab may not be an exclusively peripheral migraine treatment but has additional central effects. Whether this is due to secondary changes after peripheral modulation of sensory input or indeed represents a direct central mode of action is discussed.
引用
- Ziegeler C, Mehnert J, Asmussen K, et al. Central effects of erenumab in migraine patients: An event-related functional imaging study. Neurology. 2020. PMID: 32917805. doi:10.1212/WNL.0000000000010740
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。